Compare Indoco Remedies with TALWALKARS BETTER VAL. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TALWALKARS BETTER VALUE - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TALWALKARS BETTER VALUE 
   Change

The history of Talwalkars can be traced back to 1932 when the late Mr Vishnu Talwalkar set up the first ever gym. The tradition was continued by his son Mr Madhukar Talkwalkar who set up his first gym in 1962. Since then he and his family have worked... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TALWALKARS BETTER VALUE INDOCO REMEDIES/
TALWALKARS BETTER VALUE
 
P/E (TTM) x 50.5 -3.9 - View Chart
P/BV x 2.0 0.1 3,343.7% View Chart
Dividend Yield % 0.7 10.7 6.5%  

Financials

 INDOCO REMEDIES   TALWALKARS BETTER VALUE
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
TALWALKARS BETTER VALUE
Mar-18
INDOCO REMEDIES/
TALWALKARS BETTER VALUE
5-Yr Chart
Click to enlarge
High Rs317358 88.6%   
Low Rs178173 102.8%   
Sales per share (Unadj.) Rs113.118.6 609.3%  
Earnings per share (Unadj.) Rs4.52.8 157.9%  
Cash flow per share (Unadj.) Rs11.88.6 137.5%  
Dividends per share (Unadj.) Rs1.000.50 200.0%  
Dividend yield (eoy) %0.40.2 214.5%  
Book value per share (Unadj.) Rs73.266.9 109.5%  
Shares outstanding (eoy) m92.1531.00 297.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.214.3 15.3%   
Avg P/E ratio x55.593.9 59.1%  
P/CF ratio (eoy) x21.030.9 67.8%  
Price / Book Value ratio x3.44.0 85.1%  
Dividend payout %22.417.7 126.7%   
Avg Mkt Cap Rs m22,8308,237 277.2%   
No. of employees `0005.50.2 2,727.5%   
Total wages/salary Rs m2,20985 2,586.8%   
Avg. sales/employee Rs Th1,910.12,876.5 66.4%   
Avg. wages/employee Rs Th405.0427.0 94.8%   
Avg. net profit/employee Rs Th75.5438.5 17.2%   
INCOME DATA
Net Sales Rs m10,419575 1,811.1%  
Other income Rs m476 851.2%   
Total revenues Rs m10,466581 1,802.0%   
Gross profit Rs m1,349385 350.0%  
Depreciation Rs m677179 378.9%   
Interest Rs m235103 227.8%   
Profit before tax Rs m484109 443.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7221 338.3%   
Profit after tax Rs m41288 469.3%  
Gross profit margin %12.967.0 19.3%  
Effective tax rate %15.019.6 76.3%   
Net profit margin %4.015.2 25.9%  
BALANCE SHEET DATA
Current assets Rs m5,373792 678.1%   
Current liabilities Rs m4,157133 3,118.9%   
Net working cap to sales %11.7114.6 10.2%  
Current ratio x1.35.9 21.7%  
Inventory Days Days682 3,444.3%  
Debtors Days Days7347 156.6%  
Net fixed assets Rs m6,2443,366 185.5%   
Share capital Rs m184310 59.4%   
"Free" reserves Rs m6,5661,763 372.3%   
Net worth Rs m6,7502,073 325.5%   
Long term debt Rs m1,2331,931 63.9%   
Total assets Rs m12,3634,503 274.5%  
Interest coverage x3.12.1 148.7%   
Debt to equity ratio x0.20.9 19.6%  
Sales to assets ratio x0.80.1 659.7%   
Return on assets %5.24.2 123.4%  
Return on equity %6.14.2 144.2%  
Return on capital %9.05.3 169.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,1431 90,031.5%   
Net fx Rs m2,619-1 -206,212.6%   
CASH FLOW
From Operations Rs m1,227482 254.4%  
From Investments Rs m-1,360-491 276.9%  
From Financial Activity Rs m-388470 -82.5%  
Net Cashflow Rs m-521461 -112.9%  

Share Holding

Indian Promoters % 59.2 53.4 110.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 5.9 211.9%  
FIIs % 6.0 10.8 55.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 29.9 74.9%  
Shareholders   12,805 10,776 118.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   EDELWEISS FINANCIAL  REPCO HOME  REDINGTON  TATA INVESTMENT  KITEX GARMENTS  



Today's Market

Sensex Opens Higher; Telecom and Energy Stocks Gain the Most(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.4% while the Hang Seng is down 0.7%.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

TALWALKARS BETTER VALUE Announces Quarterly Results (1QFY20); Net Profit Down 1848.4% (Quarterly Result Update)

Aug 20, 2019 | Updated on Aug 20, 2019

For the quarter ended June 2019, TALWALKARS BETTER VALUE has posted a net profit of Rs 168 m (down 1848.4% YoY). Sales on the other hand came in at Rs 32 m (down 73.3% YoY). Read on for a complete analysis of TALWALKARS BETTER VALUE's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

TALWALKARS BETTER VALUE Announces Quarterly Results (4QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jun 7, 2019 | Updated on Jun 7, 2019

For the quarter ended March 2019, TALWALKARS BETTER VALUE has posted a net profit of Rs 65 m (up 51.2% YoY). Sales on the other hand came in at Rs 463 m (up 138.7% YoY). Read on for a complete analysis of TALWALKARS BETTER VALUE's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Nov 20, 2019 11:57 AM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - NALWA SONS INV COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS